Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real‐Life SettingMariele Gatto, Roberto Gerli, Anǵela Tincani et al.|Arthritis & Rheumatology|2020Cited by 113
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide studyLuca Iaccarino, Andrea Doria, Laura Andréoli et al.|Journal of Autoimmunity|2017Cited by 102
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic DrugsPaola Secchiero, Francesco Trotta, Federica Corallini et al.|The Journal of Rheumatology|2010Cited by 11